Dr. Eman Namati becomes CEO of NinePoint Medical — 5 points

Medical device company NinePoint Medical appointed Eman Namati, PhD, as president and CEO.

Advertisement

Here’s what you should know:

1. Dr. Namati replaces Christopher von Jako, PhD, who will now serve as an independent board member.

2. Dr. Namati will assume day-to-day leadership at the company. He will collaborate with Merit Medical Systems, which manages the sales distribution and customer service for NinePoint’s NvisionVLE Imaging System.

3. Dr. Namati joined NinePoint Medical in 2010 as a technical co-founder. He has served as research and development vice president for four years.

During his time with the company, Dr. Namati has “established a track record of building and successfully leading diverse and highly technical teams through the development and commercialization of complex medical instruments,” Board Chairman Tom Miller said.

4. Prior to joining NinePoint, Dr. Namati developed optical imaging systems as a researcher at Boston-based Massachusetts General Hospital. He helped develop the Optical Coherence Tomography technology licensed to NinePoint Medical.

5. NinePoint is pioneering the use of Optical Coherence Tomography for gastrointestinal applications. NinePoint’s NvisionVLE Imaging System provides a high-resolution, real-time scan of the esophagus using OCT.

More articles on gastroenterology:
GI leader to know: Dr. Jorge Cavazos of Gastroenterology Consultants of San Antonio
6 things to know about new ASGE President Dr. Steven Edmundowicz
GI leader to know: Dr. William Davidson III of Gastroenterology Associates

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.